Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab
Recruitment status was Not yet recruiting
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab|
- The Symbol Digit Modalities Test (SDMT) [ Time Frame: 3 years ] [ Designated as safety issue: No ]SDMT is an easily administered brief screening tool for cognitive dysfunction in MS. Patients view a key presenting nine numbers paired with symbols. Below the key is an array of symbols paired with empty spaces, the patient's task being to voice the matching number for each symbol as rapidly as possible.
- Multiple Sclerosis Inventory Cognition (MUSIC) [ Time Frame: 3 years ] [ Designated as safety issue: No ]MUSIC is a cognitive screening instrument. It assesses the cognitive core deficit in MS: mental flexibility, attention, information processing speed, memory and inhibitory control and includes also 3 items derived from a factorial analysis to examine cognitive, motor and psychosocial fatigue, respectively.
- TAP subtest Alertness [ Time Frame: 3 years ] [ Designated as safety issue: No ]TAP subtest Alertness measures the subject's ability to respond to a visual stimulus and to increase the attentional level in expectance of a stimulus of high priority. The computer-assisted test is given under 2 conditions: Simple reaction time to a visual stimulus (Greek cross) appearing at randomly varying intervals on the monitor screen is measured. In the second condition, the visual stimulus (= critical stimulus) is preceded by a cue sound presented as warning tone.
- Composite neurocognitive index [ Time Frame: 3 years ] [ Designated as safety issue: No ]Overall neurocognitive status will be assessed with a composite cognitive index score representing the sum of the scores for the individual tests: TAP subtest Alertness, MUSIC and SDMT.
|Study Start Date:||January 2011|
|Estimated Study Completion Date:||June 2014|
|Estimated Primary Completion Date:||January 2014 (Final data collection date for primary outcome measure)|
MS patients treated with natalizumab who at the beginning of the study suffer from cognitive impairment
MS patients treated with natalizumab who at the beginning of the study do not suffer from cognitive impairment
Impaired cognitive function may represent damage to brain regions that are not involved in physical functions, hence may not be detected during routine neurological assessment. Despite the high prevalence of cognitive impairment in MS, cognitive function is not assessed routinely in clinical practice. The perception that cognitive assessments are costly, time-consuming, complicated, and difficult to administer and interpret has contributed, at least in part, to the failure to incorporate cognitive testing into standard clinical evaluation of patients with MS.
Cognitive impairment may also reduce the ability of patients to comprehend and adhere to treatment concepts (Bobholz 2003). Early detection of cognitive impairment is important to initiate therapeutic intervention, even though the optimal treatment of cognitive decline in MS is at the moment controversial.
Preliminary studies suggest an essential role of disease modifying therapies (DMT) in inhibition of cognitive deterioration in patients with MS (Barak 2002, Flechter 2007). Data about long term cognitive performance of multiple sclerosis patients treated with natalizumab is limited. One study demonstrated in MS patients treated with natalizumab an improvement in SDMT (Symbol Digit Modalities Test) of 16.4% over a period of 2 years (Piehl 2010). SDMT is a screening tool for cognitive impairment in MS patients, mainly measuring working memory and speed processing. As SDMT only covers a part of the neurocognitive impairments seen in MS patients, there is a need for further studies to gain a more complete picture.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01250678
|Cantonal Hospital of Saint Gallen||Not yet recruiting|
|Saint Gallen, Switzerland, 9007|
|Contact: Murat Yildiz, MD +41 76 764 ext 11 11 email@example.com|
|Principal Investigator: Murat Yildiz, MD|
|Sub-Investigator: Stafanie Muller, MD|
|Sub-Investigator: Jochen Vehoff, MD|
|Principal Investigator:||Murat Yildiz, MD||Cantonal Hospital Saint Gallen|